Alkermes has topped consensus earnings estimates in five of its last six quarterly reports, producing an average EPS surprise of 12.4%. The only shortfall occurred in Q2 2025, when a one-time manufacturing charge weighed on results. Over that period, the company has delivered year-over-year revenue growth averaging 14%, driven primarily by sales in its central nervous system franchise. Analysts have raised full-year EPS forecasts by an aggregate $0.15 over the past three months, reflecting stronger-than-expected unit volumes and disciplined operating expense control.

The two primary factors that have historically driven Alkermes’ upside surprises remain in play. First, net positive estimate revisions: in the past 90 days, seven analysts have lifted their 2026 EPS projections, while only two have lowered them. Second, robust product momentum: the company’s flagship neurology therapy recorded a 20% sequential increase in prescription volume during Q4, outpacing management’s internal guidance range by 5 percentage points. Together, these elements suggest the upcoming report could again exceed street expectations.

On January 14, 2026, Alkermes was named to Zacks’ list of Rank #1 (Strong Buy) value stocks, joining 34 other picks selected for their attractive valuation metrics and near-term catalyst profiles. The designation reflects a forward price-to-earnings ratio of 12.8—discounted by roughly 15% relative to the specialty pharma peer group—and a projected dividend yield of 1.2%. Historically, Zacks Rank #1 stocks in the value category have delivered an average one-month gain of 4.8% following inclusion.